These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10756600)

  • 21. Quantitative assessment of oestrogen and progesterone receptors on fine-needle aspirates and cryostat sections of breast carcinomas: how does this compare with biochemical assays?
    Muchiri LW
    East Afr Med J; 1993 May; 70(5):280-3. PubMed ID: 8306903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
    Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
    Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
    Harris L; Fritsche H; Mennel R; Norton L; Ravdin P; Taube S; Somerfield MR; Hayes DF; Bast RC;
    J Clin Oncol; 2007 Nov; 25(33):5287-312. PubMed ID: 17954709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Markers of the uPA system and common prognostic factors in breast cancer.
    Minisini AM; Fabbro D; Di Loreto C; Pestrin M; Russo S; Cardellino GG; Andreetta C; Damante G; Puglisi F
    Am J Clin Pathol; 2007 Jul; 128(1):112-7. PubMed ID: 17580278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
    Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
    Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validated biomarkers: The key to precision treatment in patients with breast cancer.
    Duffy MJ; O'Donovan N; McDermott E; Crown J
    Breast; 2016 Oct; 29():192-201. PubMed ID: 27521224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissemination risk index based on plasminogen activator system components in primary breast cancer.
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    J Clin Oncol; 1999 Oct; 17(10):3048-57. PubMed ID: 10506599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined fine-needle aspiration, physical examination and mammography in the diagnosis of palpable breast masses: their relation to outcome for women with primary breast cancer.
    Steinberg JL; Trudeau ME; Ryder DE; Fishell E; Chapman JA; McCready DR; Fish EB; Hiraki GY; Ross TM; Lickley LA
    Can J Surg; 1996 Aug; 39(4):302-11. PubMed ID: 8697321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
    Eppenberger U; Kueng W; Schlaeppi JM; Roesel JL; Benz C; Mueller H; Matter A; Zuber M; Luescher K; Litschgi M; Schmitt M; Foekens JA; Eppenberger-Castori S
    J Clin Oncol; 1998 Sep; 16(9):3129-36. PubMed ID: 9738585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of cathepsin-D, CA125 and epidermal growth factor receptor in imprint smears of ovarian carcinoma.
    Athanassiadou P; Sakellariou V; Michalas S; Petrakakou E; Zerva C; Athanassiades P; Aravantinos D
    Gynecol Obstet Invest; 1997; 43(2):125-30. PubMed ID: 9067721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the tumor associated proteases cathepsin D (CATH D) and urokinase-type plasminogen activator (uPA) in cytosols of human breast cancer patients.
    Liebert A; Quietzsch D; Beier L
    Anticancer Res; 1999; 19(4A):2571-6. PubMed ID: 10470197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary breast carcinoma: immunocytochemical and immunohistochemical evaluation of biological parameters.
    Sianesi M; Bozzetti C; Del Rio P; Nizzoli R; Cascinu S
    Chir Ital; 2000; 52(6):643-5. PubMed ID: 11199998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of two ELISA for estrogen and progesterone receptor with sufficient sensitivity for fine needle aspirate and core biopsy.
    Sun CF; Wu TL; Tsao KC; Wu JT
    J Clin Lab Anal; 2001; 15(3):138-43. PubMed ID: 11344529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.